drugset / Trial / NCT06894719
Oral Tranexamic Acid After Total Knee Arthroplasty
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively. Hypothesis: Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2026-12-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tranexamic Acid | Small molecule | 1.95 g | Oral |
Indications
No indication recorded.